On the evening of April 28, Bluestar Adisseo Company(600299) released the performance report for the first quarter of 2022. Compared with the first quarter of 2021, the operating revenue increased by 15% to 3.46 billion yuan, and the net profit attributable to shareholders increased by 16% to 427 million yuan.
The company said that the double growth of operating revenue and net profit was mainly due to the substantial increase of 21% in the sales of functional products, the special contribution of liquid methionine by-products, the double-digit sales growth of digestive products and aquatic products, and the continuous growth of the sales of ruminant products. These positive factors helped Bluestar Adisseo Company(600299) offset the adverse effects of the sharp rise in raw materials, energy and transportation costs.
In terms of methionine business, both liquid and solid methionine achieved double-digit sales growth, of which liquid methionine sales increased significantly by 24%.
During the reporting period, with banc2 about to start trial operation, the methionine production capacity of Bluestar Adisseo Company(600299) will be further expanded, giving Bluestar Adisseo Company(600299) more flexibility, and strategically allocating resources between the two production platforms in Europe and China, so as to achieve the most efficient product production and delivery scheme, so as to further improve the stability of supply and business profitability.
In the first quarter of 2022, the revenue of the company’s special products business decreased compared with the first quarter of 2021, but the key product series still achieved sustained sales growth, and the digestive products business and aquatic products business achieved strong sales growth of 14% and 24% respectively; In the face of the short-term weakness in the U.S. dairy market, the sales of ruminant products business still achieved sustained growth, mainly due to the double-digit growth in China and Latin America and the continuous improvement of the market penetration of new products rumensmart and stmin ml; Driven by the increased market penetration of new products antailai and Xili selenium, the nutrition and health promotion business has achieved stable growth; Partially offset the adverse impact of the reduction in sales of feed fresh-keeping products due to the implementation of streamlining the product mix according to the sales region.
The effective integration of framelco acquisition is releasing synergy benefits in business, procurement and production. According to the company, Bluestar Adisseo Company(600299) China’s key projects are steadily advancing.
Bluestar Adisseo Company(600299) vice chairman and CEO Jean Mark said: “although the macro environment is full of variables, we believe that Bluestar Adisseo Company(600299) has the ability to overcome unprecedented challenges by virtue of our business resilience, the leading advantages established by decades of industry experience and the positive results we have achieved by taking rapid response measures in the past two years.”
